ChemInform Abstract: Rapid Construction of (‐)‐Paroxetine and (‐)‐Femoxetine via an N‐Heterocyclic Carbene Catalyzed Homoenolate Addition to Nitroalkenes.

Due to their abundance in natural products and medicinal agents, the rapid, stereodefined construction of piperidines has received considerable attention from the synthetic community. 1, 2 Specifically, the pursuit of methodologies to furnish 3- and 4- substituted piperidine rings has been the subject of particularly intense focus due to its application in the synthesis of paroxetine. Paroxetine (Paxil) is a selective serotonin reuptake inhibitor (SSRI) that was discovered in 1970 and introduced to market in 1992 as a treatment for depression, anxiety, and panic disorder. 3 A related SSRI, femoxetine, was discovered concurrently with paroxetine, but was not pursued.3 Since the initial report, many syntheses of paroxetine have appeared relying upon the establishment of a single enantiomer of N-protected trans-4-(4-fluorophenyl)-3-piperidinemethanol II, followed by coupling with sesamol and deprotection. Approaches to set the stereochemistry often depend on the chiral pool, 4 resolution, 5 chiral auxiliaries, 6 chiral base, 7 and asymmetric catalysis. 8 These methods have proven effective and are represented in the literature accordingly. However, a highly convergent synthesis in which all the carbons of paroxetine are introduced in a single stereocontrolled step is lacking. Recently, we reported a N-heterocyclic carbene (NHC) catalyzed homoenolate addition of enals to nitroalkenes allowing access to syn δ-nitroesters in good yield, excellent dr, and excellent ee.9,10 Furthermore, we developed a protocol for the in situ reduction of the syn δ-nitroesters to the corresponding trans δ-lactam. This method provides rapid access to trans 3,4-disubstituted piperidones. We envisioned that utilization of this method would allow for exceptional levels of efficiency in the syntheses of paroxetine and femoxetine. Our method is notable, as it allows for the concomitant formation of the piperidine ring and establishment of the contiguous stereocenters in a single reaction (Scheme 1). Scheme 1 NHC-Catalyzed Nitroester/Lactam Formation We began our synthesis of paroxetine by forming requisite nitro alkene 3 (Scheme 2). From commercially available aldehyde 2 we performed a Henry reaction with nitromethane followed by elimination with trifluoroacetic anhydride to furnish nitroalkene 3 in 68 % yield over two steps. With this nitroalkene in hand we were ready to attempt the key NHC-catalyzed step. Using conditions we optimized and reported in our previous publication using catalyst 1a we observed no desired lactam product 5. We hypothesized that the bulky bis-butyl/OTMS moiety of the catalyst may be too large to facilitate the reaction and explored other catalyst scaffolds (Table 1). We found that fluorinated catalyst 1b11 provides the desired lactam 5 in 82 % ee, 10:1 dr, and 58 % yield. Satisfied with these results we scaled the reaction to 9 mmol and were pleased to find the reaction proceeds smoothly, delivering 1.8 grams of product in predictable yield and selectivities. We then subjected 1.2 grams (3.55 mmol) of the lactam precursor 5 to a LAH reduction, which delivered paroxetine (Paxil) 6 in 88 % yield (1.0 grams, 3.13 mmol), for an overall yield of 35 % over 4 steps in 82 % ee. Scheme 2 Preparation of paroxetine. Reagents and conditions: a) CH3NO2, KOtBu (20 mol%), tBuOH/THF, 0 to 23 °C, quantitative; b) trifluoroacetic anhydride, Et3N, CH2Cl2, 0 °C, 68 %; c) NHC 1b, NaOAc (50 mol%), EtOH, 23 °C, 12 h, then Zn ... Table 1 Chiral Catalyst Screen. Due to its structural similarity with paroxetine, we also explored a short synthesis of femoxetine. We first synthesized nitroalkene 8 from a two-step Henry/elimination sequence to furnish nitroalkene 8 in 20 % yield over two steps (Scheme 3). We then subjected nitroalkene 8 and cinnamaldehyde to the key NHC-catalyzed step followed by in situ reduction and were pleased to observe lactam 10 in 53 % yield, 7:1 dr, and 82 % ee. Methylation of the lactam with methyl iodide followed by LAH reduction completes our synthesis of femoxetine 11 in 5 steps and 82 % ee. Scheme 3 Preparation of femoxetine. Reagents and conditions: a) CH3NO2, KOtBu (20 mol%), tBuOH/THF, 0 to 23 °C, quantitative; b) trifluoroacetic anhydride, Et3N, CH2Cl2, 0 °C, 20 %; c) NHC 1b, NaOAc (50 mol%), EtOH, 23 °C, 12 h, then Zn ... In conclusion, we have developed rapid syntheses of (-)-paroxetine and (-)-femoxetine by employing a NHC catalyzed coupling of enals and nitroalkenes. The use of fluorinated NHC catalyst 1b in a one-pot sequence provides access to lactam products in moderate yield and good stereoselectivities, which were quickly elaborated to both paroxetine and femoxetine. Further, we have demonstrated that this approach is amenable to gram scale. To the best of our knowledge, this work represents the shortest synthesis of paroxetine to date.